Skip to main content

Table 1 Demographics and Perioperative Characteristics of the HTx Recipients Stratified by eGFR

From: Incidence, risk factors and clinical outcomes of acute kidney injury after heart transplantation: a retrospective single center study

  Overall
(n = 95)
eGFR (ml/min/1.73 m2) P value
< 30 (n = 25) 30–59 (n = 61) ≥60 (n = 9)
Demographic data
 Age, years 54.31 ± 11.92 58.88 ± 9.75 55.15 ± 9.20 35.89 ± 17.20 0.0007*
 Sex, men, n (%) 81(85.26) 19(76.00) 54(88.52) 8(88.89) 0.318
 BMI (kg/m2) 24.54 ± 3.83 23.89 ± 3.15 24.70 ± 4.08 25.25 ± 3.92 0.575
 History of alcohol 29(30.53) 10(40.00) 17(27.87) 2(22.22) 0.464
 History of smoking 63(66.32) 16(64.00) 41(67.21) 6(66.67) 0.960
 Hypertension 39(41.05) 15(60.00) 21(34.43) 3(33.33) 0.083
 Diabetes mellitus 34(35.79) 12(48.00) 19(31.15) 3(33.33) 0.334
 Chronic kidney disease 20(21.05) 12(48.00) 6(9.84) 2(22.22) 0.0005*
Pretransplant characteristics
 DCM 38(40.00) 7(28.00) 26(42.62) 5(55.56) 0.279
 CAD 27(28.42) 9(36.00) 16(26.23) 2(22.22) 0.604
 Valve disease 15(15.79) 3(12.00) 10(16.39) 2(22.22) 0.756
 Pre-PCI 11(11.58) 4(16) 7(11.48) 0(0) 0.441
 ICD implantation 3(3.16) 2(8.00) 1(1.64) 0(0) 0.267
 LVAD implantation 1(1.05) 0(0) 0(0) 1(11.11) 0.008*
 Cardiac tumor 1(1.05) 0(0) 1(1.64) 0(0) 0.755
 EF pre-HTx (%) 28(23,31) 30(24,33) 26(23,30) 25(20,30) 0.257
 Creatinine (mg/dL) 1.14(0.95,1.27) 1.60(1.33,1.91) 1.10(0.95,1.22) 0.76(0.70,0.87) <.0001*
Intraoperative characteristics
 CPB duration (min) 225(183,262) 225(180,270) 220(193,255) 210(180,225) 0.822
 Blood transfusion (ml) 1440(1100,2100) 1400(1100,2000) 1440(1100,2200) 1640(1000,2050) 0.849
 Infusion (ml) 1810(1320,2440) 2000(1505,2580) 1800(1320,2350) 1700(1190,1925) 0.483
 Blood loss (ml) 1000(1000,2200) 1500(1000,2500) 1000(1000,2000) 1500(1000,2000) 0.804
 Urine volume (ml) 1800(1200,2500) 1300(770,1650) 2000(1300,2500) 2150(2000,2900) 0.001*
 IABP/ECMO 6(6.32) 4(16.00) 2(3.28) 0(0) 0.065
Postoperative characteristics
 AKI stage
  NO-AKI 62(65.26) 16(64.00) 40(65.57) 6(66.67) 0.428
  Stage 1 9(9.47) 0(0) 8(13.11) 1(11.11)  
  Stage 2 8(8.42) 2(8.00) 4(6.56) 2(22.22)
  Stage 3 16(16.84) 7(28.00) 9(14.75) 0(0)
Urine volume
 1st Day after operation 2200(1980,2805) 2100(1965,2485) 2200(1980,2735) 2525(2115,3320) 0.194
 2nd Day after operation 2125(1765,2505) 1935(1400,2498) 2135(1845,2500) 2425(2005,2970) 0.081
 3rd Day after operation 2110(1860,2050) 2050(1400,2498) 2145(1930,2450) 2305(2050,2440) 0.300
 Mechanical ventilation (min) 1080(840,2220) 1920(960,3720) 1040(783,2100) 960(720,1410) 0.134
 RRT 16(16.84) 7(28.00) 9(14.75) 0(0) 0.123
 Time from operation to discharge (days) 26(22,33) 29(23,37) 26(22,32) 24(20,26) 0.370
 Death 15(15.79) 4(16.00) 10(16.39) 1(11.11) 0.921
 Mortality in hospital 11(11.58) 4(16.00) 6(9.84) 1(11.11) 0.719
 Death within 1 year 3(3.16) 0(0) 3(4.92) 0(0) 0.422
 Follow-up days 608(303,1180) 555(341,951) 692(276,1180) 1451(497,2132) 0.199
  1. * P < 0.05; eGFR was calculated using the Chronic Kidney Disease Epidemiology collaboration equation. HTx Heart transplantation, eGFR Estimated glomerular filtration rate, BMI Body mass index, DCM Dilated cardiomyopathy, CAD Coronary arterial disease, Pre-PCI Previous percutaneous coronary intervention, ICD Implantable cardioverter defibrillator, LVAD Left ventricular assist device, CPB Cardiopulmonary bypass, RRT Renal replacement therapy. Numbers in brackets are interquartile ranges (IQRs). ANOVA was applied to the BMI variable because of its normal distribution. The Kruskal-Wallis test was used to compare other variables